An investor in China Biologic Products Holdings Inc. has criticized the biopharmaceutical company for rejecting a $3.9 billion takeover bid, saying it should consider all options to maximize shareholder value and unwind a private placement that created a controlling group of insiders.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
